The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Takeda Ditches Flu Vaccine TAK-850 from Pipeline
October 31, 2016
- Takeda’s Half-Year Sales Slip on LLP Transfer, but Profits Zoom
October 31, 2016
- Kyowa Kirin Begins Global KRN23 PIII for Pediatric X-Linked Hypophosphatemia
October 28, 2016
- Sumitomo Dainippon’s Half-Year Revenue Dips on Price Cut, Currency
October 28, 2016
- Sumitomo Dainippon to Venture into Authorized Generic Arena
October 28, 2016
- Public “IP Platforms” Necessary for Startups: IPSN President
October 28, 2016
- Daiichi Sankyo Gets US Commercialization Rights on 2 Abuse-Deterrent Opioids
October 27, 2016
- Patritumab Joins I-SPY 2 Breast Cancer Program in US: Daiichi Sankyo
October 27, 2016
- Switching Over to Biologics Should Be Considered at Early Stage in Serious Cases of Psoriasis: Dermatologist
October 27, 2016
- AZ Japan Sees Combo Holding Promise in Immuno-Oncology Race, Set to Triple Oncology Sales in 5 Years
October 26, 2016
- Wholesalers Hails Gilead Ambition to Unearth More Hep C Patients through Collaboration
October 26, 2016
- Mitsubishi Tanabe Lifts Earnings Outlook on Simponi, Vaccines
October 26, 2016
- Prof. Yamanaka Eager to Bridge Valley of Death through Takeda Collaboration
October 25, 2016
- Astellas Wins Xtandi Label Update in US for PFS Extension
October 25, 2016
- Sunovion Completes Acquisition of Cynapsus
October 25, 2016
- Shionogi Ups Earnings Forecast for April-September
October 25, 2016
- Ono Files Patent Infringement Suit over Keytruda
October 25, 2016
- Nihon Generic Takes Over 3 Brands from MSD
October 24, 2016
- Prasugrel Disappoints in PIII Study for Ischemic Cerebrovascular Disease
October 24, 2016
- 295 Staffers Applied for Voluntary Redundancy: Sumitomo Dainippon
October 24, 2016
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…